

March 20, 2025

BSE Limited Corporate Relation Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. **Scrip Code: 524404** National Stock Exchange of India Limited Listing Department Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS

Sub: Press Release

Marksans Pharma Limited's manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, has been approved by Australian TGA for manufacture of pharmaceutical formulations for Australian markets.

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa has been approved by Australian TGA for manufacture of pharmaceutical formulations in Solid Dosage Forms of Tablets and hard Capsules for Australian markets.

The products will be manufactured at the above facility in Goa India and marketed & distributed in Australian markets through the Company's subsidiary Nova Pharmaceuticals Australasia Pty Ltd.

For Marksans Pharma Limited

Harshavardhan Panigrahi Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: info@marksanspharma.com www.marksanspharma.com